Inozyme Pharma
53 articles with Inozyme Pharma
-
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/10/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.
-
Inozyme Pharma to Present at Upcoming Investor Conferences - May 03, 2022
5/3/2022
Inozyme Pharma, Inc. announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the following investor conferences:
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
4/14/2022
Inozyme Pharma, Inc. today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock.
-
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
4/12/2022
Inozyme Pharma, Inc. today announced that the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency and the second cohort in the ongoing Phase 1/2 clinical trial in ENPP1 Deficiency has been fully enrolled.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference
4/6/2022
Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13th at 8:45 AM ET.
-
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
4/4/2022
Inozyme Pharma, Inc. today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its ongoing first-in-human Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency.
-
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights
3/15/2022
Inozyme Pharma, Inc. reported financial results for the full year ended December 31, 2021, and provided recent business highlights.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
Inozyme Pharma Strengthens Management Team with Two Executive Appointments
3/8/2022
Inozyme Pharma, Inc. announced the appointment of Sanjay S. Subramanian, M.S., MBA, as chief financial officer, effective as of the later of March 21, 2022 and the date immediately following the date of the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and Soojin Kim, Ph.D., as senior vice president and chief technical operations officer.
-
Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference
3/1/2022
Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8th at 11:10 AM ET.
-
The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year.
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency- Preliminary biomarker and safety data expected in the first half of 2022 -
11/15/2021
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the first patient has been dosed in its first-in-human Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency.
-
Inozyme Pharma to Present at Upcoming Investor Conferences
11/11/2021
Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following virtual investor conferences: The 2021 Jefferies London Virtual Healthcare Conference.
-
Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights
11/9/2021
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the third quarter ended September 30, 2021, and provided recent business highlights.
-
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting
10/4/2021
Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the presentation of data from the Company’s ENPP1 Deficiency Natural History Study and its gene therapy program for the treatment of ENPP1 Deficiency.
-
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
9/22/2021
Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, at 1:20 p.m. ET.
-
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
8/11/2021
Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, reported financial results for the second quarter ended June 30, 2021, and provided recent business highlights.